Although poststroke depression is unlikely to represent a single disorder and numerous etiologies for different kinds of poststroke depression will likely emerge as the result of future research, we believe that a number of poststroke depressive disorders are likely to be the result of specific changes in brain pathology and neurophysiology. Nevertheless, there are relatively few hypotheses about the pathophysiology of poststroke depression. This paper, therefore, proposes a new hypothesis for poststroke depression involving increased production of proinflammatory cytokines resulting from brain ischemia in cerebral areas linked to the pathogenesis of mood disorders. This paper reviews the evidence supporting the hypothesis that proinflammatory cytokines are involved in the occurrence of stroke as well as mood disorders linked to the brain damage. The increased production of proinflammatory cytokines such as IL-1b, TNF-a or IL-18 resulting from stroke may lead to an amplification of the inflammatory process, particularly in limbic areas, and widespread activation of indoleamine 2,3-dioxygenase (IDO) and subsequently to depletion of serotonin in paralimbic regions such as the ventral lateral frontal cortex, polar temporal cortex and basal ganglia. The resultant physiological dysfunction may lead to poststroke depression. Future investigations may explore this hypothesis through more extensive studies on the role of proinflammatory cytokines, such as IL-1b, TNF-a or even IL-18, in patients with poststroke depression. Molecular Psychiatry (2006) 11, 984-991.
Introduction
From the earliest reports of depression and other emotional disorders following stroke, there has been an assumption that the cause of these emotional disorders in patients with stroke involves the psychological response to disability and loss. Fisher 1 described depression with cerebrovascular disease as reactive and understandable because 'the brain is the most cherished organ of humanity'.
As early as 1900, however, Meyer 2 identified several disorders such as delirium, dementia and aphasia, which he felt were the direct result of brain injury. He considered other disorders, such as depression, as arising from a combination of head injury (specifically citing that left frontal lobe and cortical convexities) as well as family history of psychiatric disorders and other premorbid vulnerabilities such as personal history of psychiatric disorder.
In accordance with these observations, in 1981, Robinson and Szetela, 3 using recently available neuroimaging techniques, found a significant inverse correlation between the severity of depression following brain injury and the distance of the anterior border of the lesion from the left frontal pole (r = 0.76, P < 0.05). In subsequent studies, Starkstein et al., 4 Astrom et al., 5 Morris et al., 6 Herrmann et al., 7, 8 Vataja et al., 9, 10 all found significant associations between left frontal and/or left basal ganglia lesions and major poststroke depression. Furthermore, Bolla-Wilson et al. 11 and Spalletta et al. 12 found an association between major depression in patients with left hemisphere stroke and cognitive impairment, while Spalletta 13, 14 found an association between unawareness of emotions and right hemisphere stroke. A systematic review of the literature and meta-analysis by Bhogal et al. 15 described that patients with left anterior lesions had a significantly increased likelihood of having major depressive disorder if they were inpatients compared to community patients (OR = 1.36; 95% CI = 1.05-1.76) or if they were in the acute stroke period compared with the chronic stroke period (OR = 2.14; 95% CI = 1.5-3.04). Thus, there is strong evidence that lesion location affecting the prefrontal-subcortical circuits, especially on the left side, is associated with the phenomenology of depression. This association is present early after the stroke and tends to disappear during the first months following the acute event. Therefore, it is conceivable that the identification of biological substrates specifically contributing to the damage of this area could further clarify the pathogenic basis of depression.
However, based on the fact that both lesion variables and impairment variables have been correlated with the existence of poststroke depression, it seems reasonable to conclude there are several kinds of depression following stroke including both secondary psychological reaction to impairment and biologically based changes in brain function. The number of papers, however, that have proposed specific biological hypotheses about the etiology of poststroke depression are few. Therefore, this paper was written to broaden the biological view of poststroke depression by briefly reviewing the biogenic amine hypothesis and then proposing a new hypothesis involving proinflammatory cytokines. Considering the very high prevalence of depression after stroke (about 33%) and its negative impact on cognitive and functional performance, understanding the pathophysiological mechanisms of poststroke depression is not a mere theoretical exercise but it has important clinical implications for treatment and rehabilitation.
Materials and methods
A detailed search of the medical literature was conducted. Search materials included Medline and PubMed databases utilizing research words of poststroke depression and cytokines, stroke and cytokines, and depression and cytokines. A total of 2809 articles were screened for inclusion. In addition, the bibliographies of all relevant articles were searched for further publications. All articles cited in this manuscript were judged by both GS and PB to be relevant and to meet rigorous scientific standard of conduct.
Results/discussion
Biological hypotheses about the etiology of post-stroke depression I. Biogenic amine theory. The first detailed hypothesis about a pathophysiological etiology of poststroke major depression was proposed by Robinson and Bloom. 16 Based on the work of Reis et al. 17 in the 1970s, which demonstrated that injury to axonal projections of biogenic amine containing neurons led to a shutdown of neurotransmitter production, Robinson and Bloom 16 hypothesized that ischemic brain lesions may interrupt the ascending biogenic amine containing axons from the brainstem to the cortex leading to a decrease in the overall production of serotonin or norepinephrine in uninjured areas of the axonal tree. The subsequent dysfunction of strategic limbic structures in frontal and temporal cortex as well as basal ganglia could lead to clinical symptoms of depression. The experimental evidence to support the biogenic amine theory hypothesis included the finding that poststroke patients with depression had significantly lower concentrations of 5-hydroxy indoleacetic acid (5-HIAA), a metabolite of serotonin in CSF, compared to the age, gender and hemispheric lesion location matched nondepressed stroke patients 18 and that patients with left hemisphere stroke showed a significant inverse correlation between serotonin 5-HT 2 receptor binding as measured by 11 C N-methyl spiperone in their left temporal cortex and Hamilton Depression score (r = 0.76, P < 0.05).
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II. Cytokines in stroke. Several studies have reported prominent changes in proinflammatory cytokines following stroke. [20] [21] [22] The proinflammatory cytokines interleukin (IL)-1, tumor necrosis factor a (TNF-a), IL-6 and IL-8 have all been shown to be involved in the initiation or amplification of the inflammatory response in patients following acute cerebral ischemia. Interestingly for our purposes, some studies on experimental models have suggested that inflammatory mediators, such as the cytokine IL-1, might contribute to the extent of cerebral ischemia through their effects on specific limbic pathways. 23 These animal data strongly support the view that lesion-caused dysregulation of proinflammatory cytokine activity may augment the mechanisms which produce neuronal loss in those limbic areas hypothesized to play a role in the pathogenesis of poststroke depression.
Specifically, IL-1 is a family of pleiotropic cytokines produced by mononuclear phagocytes in response to a variety of stimuli (e.g., bacteria, irritants, injury, etc.) and it appears to play an important role in the initiation and maintenance of the inflammatory response following injury, as well as the induction of immune response. IL-1 is produced at the site of inflammation and triggers the inflammatory cascade by activating surrounding cells to produce chemokines which attract polymorphonuclear leukocytes, monocytes, and T-lymphocytes, as well as other cytokines (IL-6, IL-2, IL-4). The production and activity of IL-1 is tightly regulated; dysregulation can lead to persistence of inflammation and anomalous immune responses. Perhaps because of the need for tight regulation, IL-1 constitutes a whole system composed of agonist proteins (IL-1a and IL-1b), antagonist proteins (IL-1RA) and binding receptor molecules with signaling or decoy ability. 24 IL-1 was the first cytokine identified in brain and numerous studies (see review by Allan et al. 24 and Rothwell 25 ) have suggested that IL-1 and, in particular, IL-1b, which can be produced by activated microglia following diverse forms of neurodegeneration and CNS inflammation, plays a major role in cerebral ischemic damage. In contrast, the IL-1RA has neuroprotective effects in both rodents and humans. 24, 26, 27 Patients with ischemic stroke were found to have increased levels of IL-1b 28 and elevated IL-1b mRNA in mononuclear cells. 29 Furthermore, studies of the IL-1 and IL-1RA genes suggest that polymorphisms in both IL-1a and IL-1RA genes may be associated with increased risk of stroke. [30] [31] [32] Similarly, TNF-a has been hypothesized to play an important role in neurodegeneration. 33 TNF-a release from blood cells and serum levels of TNF-a were found to be elevated during the acute phase following stroke compared with healthy controls. [34] [35] [36] Furthermore, increased levels of TNF-a in the cerebral spinal fluid and serum of acute stroke patients has been associated with increased severity of postischemic neuropathology 37 and polymorphism of the TNF gene have been associated with susceptibility to ischemic stroke. 32 IL-6 is a pleiotropic cytokine involved in inflammatory processes and like IL-1 is able to induce acute inflammatory responses such as fibrinogen and C-reactive protein production. The C-reactive protein, an important peripheral inflammatory marker, is strongly associated with risk for stroke. [38] [39] [40] Although a clear picture of the role of IL-6 in stroke has not yet been elucidated, an increase in IL-6 production following cerebral ischemia has been described in several clinical studies 21, 34, 41, 42 and elevated levels of the IL-6 cytokine have been correlated with severity and clinical outcome of stroke. 28, 43, 44 Furthermore, polymorphisms of the promoter IL-6 gene have been associated with stroke 45, 46 and the IL-6 system has been associated with acute inflammatory response after stroke. 47 In addition, the IL-8 chemokine has also been associated with the recruitment of inflammatory cells and is increased in stroke patients. 48, 49 It has been associated with amplification of the secondary inflammatory process following stroke. 50, 51 Finally, emerging data indicate that the cytokine IL-18, which seems to play a key role in neuroinflammation and neurodegeneration, is able to mediate delayed neuroinflammatory processes in experimental hypoxic-ischemic brain injury and is involved in stroke-induced neuroinflammation in humans (reviewed by Felderholf-Mueser et al. 52 ). IL-18 is a recently identified member of proinflammatory cytokines, which belongs to the IL-1 family. 53, 54 It is a unique cytokine with a wide spectrum of biological actions, ranging from the ability to induce interferon (IFN)-g, to regulate the synthesis of other inflammatory cytokines and to modulate the function of many immunocompetent cells, such as macrophages, microglia, monocytes, lymphocytes, granulocytes and dendritic cells. Its blockade has even been shown to ameliorate diseases in preclinical studies. 55, 56 Ubiquitously present in the brain, being produced by astrocytes and microglia, 57,58,52 IL-18 seems to contribute to inflammatory responses in the brain, perhaps by a different mechanism compared to IL-1. 59 Moreover, IL-18 has been described to be a marker of cardiovascular diseases leading to growth and vulnerability of atherosclerotic plaques, 60, 61 and therefore it could likely participate in the development of ischemic brain injury, as found in hypoxic-ischemic animal models, and in focal ischemia in humans. 62, 63 Although one study has suggested that IL-18 does not contribute to acute ischemic brain damage in a mouse model, 64 the evidence that elevated levels of plasma IL-18 can be identified in patients with stroke and that the quantification of initial circulating IL-18 levels could be helpful in predicting the outcome following cerebral ischemia, 65 supports the role of IL-18 in human stroke pathophysiology and suggests that further studies are needed to elucidate the mechanisms involved.
During the inflammatory response, an anti-inflammatory state, characterized by increased levels of molecules able to directly block the binding of proinflammatory stimuli to their cell surface receptors (such as IL-1RA) or able to induce an antiinflammatory state on their own (such as TGF-b and IL-10), is generally coexisting with the increased levels of proinflammatory cytokines. During the stroke pathophysiological processes, an alteration of anti-inflammatory molecules has been also described in humans. More in detail, IL-1RA and TGF-b are over expressed after ischemic stroke, 66, 67 whereas circulating IL-10 have been found to be lower in patients than in controls 68 and have been associated with more extensive pathology. 69 Thus, it is well-established that cytokine network plays an important role in the initiation and maintenance of damage-related inflammation in patients suffering from stroke.
III. Role of cytokines in psychiatric disorders. The evidence of involvement of cytokines, and in particular proinflammatory cytokines, in the etiology of psychiatric disorders is numerous and has been reviewed by many authors. [70] [71] [72] Administration of proinflammatory cytokines, such as IL-1b and TNF-a can induce a depressive-like behavior in mice, which resembles the vegetative symptoms of depression in humans. 73, 74 In addition, disorders which affect the immunological system such as autoimmune disorders or chronic viral infections such as HIV are often associated with depressive disorders. Several investigators [75] [76] [77] [78] have found increased levels in IL-1b in patients with dysthymia or major depressive disorder. Similarly, TNF-a has been found to be increased in the plasma of patients with depressive mood 79 or with major depressive disorder 80 and even IL-6 has sometimes been found to be over expressed in elderly patients with major depressive disorder. 79, 81, 82 Two studies have also found that IL-18 was over expressed in serum of patients with depression. 83, 84 Furthermore, probably as a result of immune dysregulation, antiinflammatory cytokines have been described to be altered in depression, since both IL-1RA and IL-10 have been found to be increased in serum of patients with major depression, [85] [86] [87] although these results were not always statistically significant. Unfortunately, proinflammatory cytokines would be too toxic to be used directly in human therapy. Thus, they cannot be used in humans for experimental purposes. However, cytokines generally used in immunotherapy, which are not per se proinflammatory but which have a cytokine network perturbation effect leading to proinflammatory molecule release, can cause depression [88] [89] [90] and antidepressant therapy can prevent or attenuate cytokine induced depression. 91, 92 Therefore, this indirect evidence suggests that proinflammatory cytokines may be part of the pathogenesis of mood disorders in humans. These findings are summarized in Table 1 .
The potential mechanisms involving proinflammatory cytokines leading to depression are numerous: the cytokine activation might induce alterations in brain function analogous to the biological abnormalities occurring in depressed patients, including increased activity of the hypothalamus-pituitaryadrenal (HPA) axis and altered neurotransmission. Several studies have reported findings consistent with this hypothesis. For example, IL-1, TNF-a and IL-6 are potent stimulators of the HPA axis activity characterized by increases in ACTH and cortisol. 93 Moreover, IL-1 and TNF-a are able to influence noradrenergic activity and systemic administration of IL-1b and TNF-a increased norepinephrine (NE), dopamine (DA) and serotonin (5-HT) metabolism in several hypothalamic nuclei, as well as at limbic sites. 94 Cytokines may also induce depressive symptoms by affecting the serotonergic system. In fact, some cytokines, such as IFN-g, IFN-a, TNF-a and IL-1, have all been shown to upregulate the enzyme indoleamine 2,3-dioxygenase (IDO) expression [95] [96] [97] [98] and, thus, cause increased metabolism of tryptophan, resulting in decreased availability of tryptophan to synthesize 5-HT. It has also been shown that patients treated with cytokines had decreased blood levels of tryptophan 99 and therefore it is very likely that cytokines can suppress serotonin by activating IDO that catabolizes tryptophan. Finally, an IL-18 involvement in depression, although still not supported by experimental data, is intriguing and recent results indicate that IL-18 is able to induce IDO expression. 100 Based on the reported evidence, the correlation between cytokine induced brain damage, the likely localization of the event in limbic areas causing depression and the perturbation of neurotransmitters strictly linked to depression, converge. Unfortunately, so far no data exist in poststroke depression research.
IV. Cytokine hypothesis. Based on the strong association of proinflammatory cytokines with ischemic brain injury and the evidence suggesting that a role for interleukins may exist with respect to the pathophysiology of certain subtypes of depression, a new hypothesis on poststroke depression etiology can be proposed (Figure 1) . The cytokineserotonin interaction through IDO enzyme could play a pivotal role in poststroke depression with the following sequence of events: the increased production of proinflammatory cytokines (such as IL-1b, TNF-a and even IL-18) resulting from stroke leads to amplification of the inflammatory process and to widespread activation of the IDO enzyme and subsequently widespread decrease in the production of serotonin. Serotonergic depletion in strategic brain regions such as paralimbic areas of left frontal and temporal cortex may ultimately lead to depression.
Although the hypothesis that proinflammatory cytokines may mediate poststroke depression is intriguing, it should be pointed out that it will be difficult to prove that any of the proposed cytokines is central to the mechanism of poststroke depression. Cytokines and their related molecules may have additive, synergistic or sometimes antagonistic actions. Moreover, redundant pathways and other still unidentified molecules may be involved in regulating the cytokine network. Furthermore, the majority of data indicating brain cytokine involvement in depressive diseases are based on animal studies and are difficult to extrapolate to humans. Studies in patients are Table 1 The cytokine-mediated depression hypothesis
Findings References
Administration of proinflammatory cytokines in animals induce a depression-like status 73, 74 Depression has been reported to accompany diseases affecting the immune system (HIV, autoimmune illnesses) where cytokines are strongly dysregulated 71 Patients with depression have increased level of proinflammatory cytokines [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] Cytokine therapy may cause depression as side effect 72, [88] [89] [90] [91] [92] Antidepressive drugs may prevent depression induced by cytokine therapy in human 91, 92 Antidepressive drugs may have a cytokine-linked anti-inflammatory effect 91, 106, 107 Inhibitors of proinflammatory cytokines may relieve depressive symptoms in humans 108 Anti-inflammatory drugs able to inhibit proinflammatory cytokine production may have antidepressive effect 109 mainly based on cytokine plasma level determinations and such circulating molecule concentrations do not necessarily reflect the activity of cytokines within the CNS. The activation of brain cytokines might involve different mechanisms and currently it is not possible to measure cytokines in specific areas of living human brain. Despite these methodological limitations, future clinical studies should examine a broader set of cytokines in relation to poststroke depression. In particular IL-18, here proposed as a new player in the hypothesized mechanism of stroke and depression should be investigated. Moreover, the fact that IL-18 seems to mediate delayed neuroinflammatory events after hypoxic-ischemic brain injury, 101 makes this cytokine particularly interesting in the design of a tentative correlation between temporal expression in the brain of stroke-induced cytokines and the activation of poststroke biological mechanisms leading to depression. In this respect, the observation that during the pathophysiological process of stroke, anti-inflammatory cytokines are produced at a later time 68 than inflammatory cytokines, provides a rational for further studies aimed to clarify differences in early versus delayed onset poststroke depression pathogenesis.
Eventually, the cytokine hypothesis may provide a missing link to explain why poststroke depression leads to impaired physical and cognitive recovery and increased mortality. [102] [103] [104] [105] Ultimately, a better understanding of the role of cytokines in the mechanism of stroke depression and poststroke depression may lead to new and more etiologically specific treatment for these disorders. 
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